Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PRTA
SELLProthena Corporation plc · Healthcare · Ireland · $458M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Prothena Corporation plc is a clinical-stage neuroscience company specializing in the discovery and development of novel antibodies and immunotherapies for neurodegenerative diseases. Its robust pipeline targets critical protein misfolding conditions such as amyloidosis, Parkinson's, and Alzheimer's disease. The company leverages deep scientific expertise in protein dysregulation to create targeted treatments addressing significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.9M | 91.4M | 135.2M | 9.7M | -43.6% | 57.9M | 83.3M | 22.0M | 50.7% |
| EPS | -2.47 | -2.76 | -2.27 | -4.53 | — | -2.82 | — | — | — |
| Shares | 52.1M | 53.7M | 53.8M | 53.8M | +3.3% | 52.4M | — | — | — |
| Debt | 6.5M | 11.8M | 10.8M | 8.4M | 9.0% | 7.7M | — | — | — |
| Equity | 622.0M | 561.4M | 486.9M | 280.5M | -23.3% | — | — | — | — |
| Op CF | -108.8M | -133.9M | -150.1M | -163.6M | — | -81.3M | — | — | — |
| Inv CF | -0.5M | -2.8M | -0.3M | -0.1M | — | — | — | — | — |
| Fin CF | 241.5M | 45.1M | 1.6M | -0.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRTA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PRTA | Prothena Corporation plc(you) | $458M | 28 | SELL |
| GHRS | GH Research PLC | $1.9B | 34 | SELL |
| AMRN | Amarin Corporation plc | $284M | 45 | HOLD |
| COPN.SW | Cosmo N.V. | $1.4B | 19 | STRONG SELL |
| JAZZ | Jazz Pharmaceuticals plc | $15.9B | 88 | STRONG BUY |
| 0RGI.L | Cosmo Pharmaceuticals N.V. | $1.8B | 17 | STRONG SELL |
| PRGO | Perrigo Company plc | $1.4B | 51 | HOLD |
| UPR.L | Uniphar plc | $1.4B | 67 | BUY |
| ICLR | ICON Public Limited Company | $12.8B | 57 | HOLD |
| ALKS | Alkermes plc | $8.8B | 78 | BUY |
Peer medians: ROE 1.8% · P/E 23.4x · Gross margin 48.5%